Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.75 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.75 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.75 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.75 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.75 |
| ▸ | ATIC | P31939 | 3/20 | 0.75 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.75 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.75 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 1/20 | 0.75 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL21600667 | 1.00 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15569564 | 1.00 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL16767007 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL28545416 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL16767008 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934793 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL108860 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL28552890 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3760710 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2992874-B1 | LIPOSOME FOR TOPICAL ADMINISTRATION AND APPLICATION THEREOF | DELTA FLY PHARMA INC (JP) | 2018-08-08 | — | — | EP | claimed |
| CN-105142613-B | Local administrable liposome and application thereof | 德尔塔菲制药股份有限公司 | 2018-03-16 | — | — | CN | claimed |
| EP-2716304-B1 | A LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF | DELTA-FLY PHARMA INC (JP) | 2017-10-11 | — | — | EP | claimed |
| US-9745583-B2 | Liposome for topical administration and application thereof | DELTA-FLY PHARMA, INC. (JP) | 2017-08-29 | — | — | US | claimed |
| CN-103561775-B | Comprise liposome of shRNA molecule of anti-thymidylate synthetase and application thereof | 德尔塔菲制药股份有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-20160208263-A1 | LIPOSOME FOR TOPICAL ADMINISTRATION AND APPLICATION THEREOF | DELTA-FLY PHARMA, INC. (JP) | 2016-07-21 | — | — | US | claimed |
| EP-2992874-A1 | LOCALLY ADMINISTERED LIPOSOME AND APPLICATION THEREFOR | Delta-Fly Pharma, Inc. (JP) | 2016-03-09 | — | — | EP | claimed |
| CN-105142613-A | Locally administered liposome and application therefor | DELTA FLY PHARMA INC | 2015-12-09 | — | — | CN | claimed |
| CN-103561775-A | Liposome containing shRNA molecule for thymidylate synthase, and use for same | DELTA FLY PHARMA INC | 2014-02-05 | — | — | CN | claimed |
| US-8592572-B2 | Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof | DELTA-FLY PHARMA, INC. (JP) | 2013-11-26 | — | — | US | claimed |
| US-20130058996-A1 | LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF | DELTA-FLY PHARMA, INC. (JP) | 2013-03-07 | — | — | US | claimed |
| US-12577307-B2 | Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor | GENENTECH, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12486504-B2 | Drug delivery composition, method for producing same and use thereof | Yamamoto, Hirofumi (JP) | 2025-12-02 | — | — | US | disclosed |
| US-20250288554-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS-DERIVED HEPATOCARCINOMA | SEAKNIT BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20240360222-A1 | ANTIBODY | OSAKA UNIVERSITY (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20120045446-A1 | THERAPEUTIC AGENT FOR DISEASES IN WHICH NEOPLASTIC PROLIFERATION OF PLASMA CELLS OCCURS | OSAKA UNIVERSITY (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2418222-A1 | THERAPEUTIC AGENT FOR DISEASES IN WHICH NEOPLASTIC PROLIFERATION OF PLASMA CELLS OCCURS | Osaka University (JP) | 2012-02-15 | — | — | EP | disclosed |
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | NISHIO TETSUYA (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | CYP2D6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GART 1782/4885DHFR 395/4885TYMS 3352/4885 |
| US-12577307-B2 | Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor | PDCD1, CD274, PDCD1LG2 | GART 3371/4885DHFR 1785/4885TYMS 792/4885 |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | GART 3627/4885DHFR 1114/4885TYMS 4056/4885 |
| US-20250288554-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS-DERIVED HEPATOCARCINOMA | FABP1, SLC10A1, HDGF | GART 2933/4885DHFR 2349/4885TYMS 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.